INTRODUCTION
Antibiotic resistance in Gram-positive bacteria is steadily increasing, posing a growing health concern worldwide [1, 2] . Likewise, antibiotic treatment failures have been reported among children with invasive infections caused by resistant
Gram-positive bacteria [3, 4] .
Management of these infections in pediatric patients may be even more challenging due to limited therapeutic options. Antibiotics approved by the US Food and Drug Administration (FDA)
for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in children are limited to vancomycin, clindamycin and linezolid [5] . Daptomycin has been increasingly used in pediatrics despite the lack of safety and efficacy data [6] . Finally, for newer antibiotics such as telavancin, dalbavancin and oritavancin, the lack of pharmacokinetic and clinical studies severely restricts their use in pediatric infections [7] .
Ceftaroline is a new cephalosporin with an FDA-approved indications for acute bacterial skin and skin structure infections (ABSSI) caused by MRSA and community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae and other susceptible bacteria in children 2 months of age and older [8] . In this review, the microbiological profile of ceftaroline, its mechanism of action, and pharmacokinetic characteristics will be presented. Additionally, clinical evidence for use in pediatric patients will be discussed.
Compliance with Ethics Guidelines
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
Antimicrobial Activity and Pharmacology of Ceftaroline
Ceftaroline is known as a novel ''fifth-generation cephalosporin'' that exhibits in vitro bactericidal activity against MRSA [9, 10] . It is also active against other bacteria common in childhood infections, such as S. pneumoniae, S. pyogenes, Haemophilus influenzae and Moraxella catarrhalis [11] . Ceftaroline, like other b-lactams, exerts bactericidal effects by binding to penicillin-binding proteins (PBPs) to inhibit cell wall synthesis [12] . Ceftaroline is distinguished from other b-lactams by its enhanced affinity for mutated PBPs that render other b-lactams ineffective against S.
aureus and S. pneumoniae [13] . In S. aureus, the mecA gene-encoded mutant PBP2a confers methicillin resistance while b-lactam resistance in S. pneumoniae results from modification in PBP1A, PBP2X, and PBP2B [14, 15] . Unlike other The pharmacodynamic (PD) parameter most predictive of efficacy is the percentage of the dosing interval during which serum-free ceftaroline concentration remains above the MIC (%fT [ MIC). In a study using murine thigh and lung infection models, the average %fT[MIC needed for bacteriostasis was 26 ± 8% for S. aureus and 39 ± 9% for S. 
Clinical Efficacy and Safety

FDA-Labeled Indications
In May 2016, the FDA approved ceftaroline for the treatment of ABSSI and CABP among children as young as 2 months of age [8] . This approval was based on two randomized, controlled observer-blinded studies primarily evaluating safety in children [38, 39] . Study doses were essentially the same as what is currently approved (Table 1) , with the exception of increasing the dose from 8 mg/kg to 12 mg/kg every 8 h for children 6 months-2 years of age. Additionally, the study allowed for a maximum dose of 400 mg every 8 h, but did not offer the alternative option of 600 mg every 12 h as appears in the package insert.
The CABP study compared ceftaroline to ceftriaxone 75 mg/kg/day (maximum daily dose of 4 g) and excluded patients with suspected MRSA or Pseudomonas spp., or requiring intensive care unit (ICU) admission.
Patients in both groups were treated for a mean total of 10 days including initial intravenous (IV) antibiotics for a minimum of 3 days plus transition to oral therapy, which was typically amoxicillin/clavulanate [38] . Within the modified intent-to-treat (mITT) population (i.e. received at least one dose of study drug), clinical cure rates were comparable with 88% (n = 94/107) success in the ceftaroline group and 89% (n = 32/36) in the comparator group at 
